National and Kapodistrian University of Athens
Κλινική αξιολόγηση της έκφρασης του γονιδίου KLK6 που κωδικοποιεί την καλλικρεΐνη 6 στον καρκίνο του μαστού
Abstract
dc:descriptionBreast tumors exhibit vast heterogeneity reflected by diverse biological and molecular features, prognostic outcomes and response to therapy. Novel molecular markers that provide meaningful prognostic information for breast cancer patients are needed. According to previous research studies, expression of KLK family members is often associated with clinical outcome of breast cancer (BC) patients. More than that, Kallikrein-related peptidase 6 (KLK6) was previously reported to be implicated in BC and thus may prove a useful molecular tool for clinical management. The purpose of the present study was to assess the clinical value and prognostic potential of KLK6 mRNA expression in BC.Total RNA was extracted from 165 breast tumors, as well as 100 adjacent non-cancerous tumor specimens. After complementary DNA (cDNA) synthesis and following quality control, KLK6 mRNA levels were analysed using quantitative real-time PCR. Receiver operating characteristic curves were constructed in order to assess the ability of KLK6 mRNA expression levels to differentiate between molecular BC subtypes. Survival analyses, using DFS as endpoint, were performed at the univariate and multivariate levels. Publicly available BC databases and online survival analysis tools were used to validate our findings.A significant downregulation of KLK6 mRNA expression was observed in BC tissue sections compared to the non-cancerous component (P<0.001). The expression of KLK6 is positively associated with tumor grade (P=0.038) and the gene is overexpressed in aggressive phenotypes such as TNBC and HER2-positive tumors (P<0.001). Aberrant KLK6 expression predicts the clinical outcome of BC patients in terms of DFS, independently of currently used prognostic markers (HR=7.11, 95%CI = 1.19-42.45). The differential expression of KLK6 and its association with unfavourable outcome in BC patients was validated via in silico analyses.To our knowledge, this is the first study to provide evidence of the clinical value and prognostic potential of KLK6 mRNA expression in BC. Although an independent external cohort is necessary to confirm our findings, we indicate the potential of KLK6 to discriminate between BC subtypes and its robust and independent association with BC patient outcome.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Haritos, Christoforos
- Χαρίτος, Χριστόφορος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43126